Martin Charlie
Leistritz Extrusion, Leistritz North America, 175 Meister Avenue, Somerville, New Jersey, 08876, USA.
AAPS PharmSciTech. 2016 Feb;17(1):3-19. doi: 10.1208/s12249-016-0485-3. Epub 2016 Feb 16.
Developed approximately 100 years ago for natural rubber/plastics applications, processes via twin screw extrusion (TSE) now generate some of the most cutting-edge drug delivery systems available. After 25 or so years of usage in pharmaceutical environments, it has become evident why TSE processing offers significant advantages as compared to other manufacturing techniques. The well-characterized nature of the TSE process lends itself to ease of scale-up and process optimization while also affording the benefits of continuous manufacturing. Interestingly, the evolution of twin screw extrusion for pharmaceutical products has followed a similar path as previously trodden by plastics processing pioneers. Almost every plastic has been processed at some stage in the manufacturing train on a twin screw extruder, which is utilized to mix materials together to impart desired properties into a final part. The evolution of processing via TSEs since the early/mid 1900s is recounted for plastics and also for pharmaceuticals from the late 1980s until today. The similarities are apparent. The basic theory and development of continuous mixing via corotating and counterrotating TSEs for plastics and drug is also described. The similarities between plastics and pharmaceutical applications are striking. The superior mixing characteristics inherent with a TSE have allowed this device to dominate other continuous mixers and spurred intensive development efforts and experimentation that spawned highly engineered formulations for the commodity and high-tech plastic products we use every day. Today, twin screw extrusion is a battle hardened, well-proven, manufacturing process that has been validated in 24-h/day industrial settings. The same thing is happening today with new extrusion technologies being applied to advanced drug delivery systems to facilitate commodity, targeted, and alternative delivery systems. It seems that the "extrusion evolution" will continue for wide-ranging pharmaceutical products.
双螺杆挤出(TSE)工艺大约在100年前开发用于天然橡胶/塑料应用,如今已产生了一些最前沿的药物递送系统。在制药环境中使用了大约25年后,TSE工艺相对于其他制造技术具有显著优势的原因已变得显而易见。TSE工艺具有良好的特性,易于放大和工艺优化,同时还具有连续制造的优点。有趣的是,用于药品的双螺杆挤出技术的发展历程与塑料加工先驱者之前走过的道路相似。几乎每种塑料在制造过程中的某个阶段都在双螺杆挤出机上进行过加工,该挤出机用于将材料混合在一起,以使最终产品具有所需的性能。本文讲述了自20世纪初/中叶以来TSE工艺在塑料加工方面的发展历程,以及从20世纪80年代末至今在制药领域的发展历程。两者的相似之处显而易见。本文还描述了同向旋转和反向旋转TSE用于塑料和药物连续混合的基本理论和发展情况。塑料和制药应用之间的相似之处非常显著。TSE固有的卓越混合特性使其在其他连续混合器中占据主导地位,并促使人们进行了大量的开发工作和实验,从而产生了我们日常使用的商品和高科技塑料制品的高度工程化配方。如今,双螺杆挤出是一种经过长期考验、久经验证的制造工艺,已在每天24小时的工业环境中得到验证。如今,同样的事情也在发生,新的挤出技术被应用于先进的药物递送系统,以促进商品、靶向和替代递送系统的发展。看来,“挤出技术的演变”将在广泛的药品中持续下去。